NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

HEALTH TECHNOLOGY APPRAISAL PROGRAMME

Equality impact assessment – Scoping

STA Bimekizumab for treating active psoriatic arthritis [ID4009]

The impact on equality has been assessed during this appraisal according to the principles of the NICE equality scheme.

inciples of the NICE equality scheme.	
1.	Have any potential equality issues been identified during the scoping process (draft scope consultation and scoping workshop discussion), and, if so, what are they?
No	
2.	What is the preliminary view as to what extent these potential equality issues need addressing by the committee?
N/A	
3.	Has any change to the draft scope been agreed to highlight potential equality issues?
N/A	
4.	Have any additional stakeholders related to potential equality issues been identified during the scoping process, and, if so, have changes to the matrix been made?

Technology appraisals: Scoping

Equality impact assessment for the single technology appraisal of bimekizumab for treating active

psoriatic arthritis [ID4009] Issue date: April 2023

	No	
_	Approved by Associate Director (name):Linda Landells	
	Date: 3 February 2023	

Technology appraisals: Scoping Equality impact assessment for the single technology appraisal of bimekizumab for treating active psoriatic arthritis [ID4009]

İssue date: April 2023 2 of 2